ligand-binding domain (LBD) , which can compromise how well treatments bind to the oncogene.
: It examines the ability of the mutant proteins to exchange nuclear co-repressors for co-activators, which is a critical factor in how the body responds—or fails to respond—to therapy. 24010.rar
: The research tracks how certain mutations (like the L398P variant) affect the protein's breakdown when exposed to ATRA/Arsenic Trioxide (ATO) combination treatments. ligand-binding domain (LBD) , which can compromise how
If this is the scientific context you are looking for, the primary features related to this data include: ligand-binding domain (LBD)